Holen Sie sich die Stockscreener-App
8.69
5.13%
-0.47
Handel nachbörslich:
8.69
Schlusskurs vom Vortag:
$9.16
Offen:
$9.17
24-Stunden-Volumen:
1.36M
Relative Volume:
1.24
Marktkapitalisierung:
$1.39B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-7.2417
EPS:
-1.2
Netto-Cashflow:
$-90.59M
1W Leistung:
-20.71%
1M Leistung:
-23.30%
6M Leistung:
+40.84%
1J Leistung:
+281.14%
1-Tages-Spanne:
$8.62
$9.20
1-Wochen-Bereich:
$8.62
$11.12
52-Wochen-Spanne:
$2.145
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| OCUL | 8.69 | 1.39B | 61.10M | -138.36M | -90.59M | -1.20 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Ocular Therapeutix Posts Mixed Third Quarter 2024 Results - Vision Monday
Ocular Therapeutix Reports Q3 2024 Financial Results - TipRanks
Ocular Therapeutix: Q3 Earnings Snapshot - Milford Mirror
Avoro Capital Advisors LLC Acquires Significant Stake in Ocular Therapeutix Inc - GuruFocus.com
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ocular Therapeutix Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc Reports Q3 2024 Earnings: Revenue at $15. - GuruFocus.com
Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus.com
Ocular Therapeutix appoints Namrata Saroj as CBO - The Pharma Letter
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights - The Manila Times
Ocular Therapeutix Inc. Appoints Namrata Saroj, OD, as Chief Business Officer - Vision Monday
A Peek at Ocular Therapeutix's Future Earnings - Benzinga
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV - The Manila Times
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnin - GuruFocus.com
Ocular Therapeutix™ to Present at the Jefferies London - GlobeNewswire
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings - Yahoo Finance
Ocular Therapeutix appoints new Chief Business Officer By Investing.com - Investing.com Canada
Ocular Therapeutix Inc. (OCUL) Quarterly 10-Q Report - Quartzy
Ocular Therapeutix appoints new Chief Business Officer - Investing.com
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer - The Manila Times
Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024 - GlobeNewswire
Rosalind Advisors Inc. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 By Investing.com - Investing.com South Africa
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 - Investing.com India
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Drops By 18.1% - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - MSN
HC Wainwright Reaffirms “Buy” Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World
SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week HighTime to Buy? - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.34 - Investing.com
Ocular Therapeutix stock soars to 52-week high of $11.34 By Investing.com - Investing.com UK
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load? - Simply Wall St
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 4.9%Here's Why - MarketBeat
Ocular Therapeutix shares hold as analyst reiterates Buy rating By Investing.com - Investing.com UK
Ocular Therapeutix Inc (OCUL) expanding its growth trajectory ahead - SETE News
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):